COMMUNIQUÉS West-GlobeNewswire

NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
21/11/2025
Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program The ability to attract [...]
Seren Advanced Dentistry Oxnard Announces Implementation of Biomimetic Conservative Dentistry Led by Dr. Ette Ntekim
21/11/2025
Oxnard, CA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Seren Advanced Dentistry Oxnard today formally announced the introduction of biomimetic conservative dentistry as part of its restorative care offerings. The announcement [...]
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
21/11/2025
WILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of [...]
Channel Medsystems Appoints Robert Brown, MBA, CPA, as Chief Financial Officer
20/11/2025
BERKELEY, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Channel Medsystems, Inc., a privately held company dedicated to advancing women’s health with innovative solutions, announced today the appointment of Robert Brown, [...]
MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors
20/11/2025
MiNK-215, an IL-15 armoured FAP-targeting CAR-iNKT, targets and clears tumor-protective FAP+ fibroblasts to allow immune cells to infiltrate and kills cancer cells Activates multiple immune pathways to generate potent, [...]
GENFIT annonce la réalisation du retrait volontaire de ses « American Depositary Shares » du Nasdaq Stock Market
20/11/2025
Lille (France), Cambridge ( Massachusetts, États-Unis), Zurich (Suisse), le 20 novembre 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de [...]
GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
20/11/2025
Lille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); November 20, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare [...]
SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
20/11/2025
Ghent - Belgium, Nov. 20, 2025 (GLOBE NEWSWIRE) -- SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM PRESS RELEASE REGULATED INFORMATION – [...]
GENFIT : Information financière du troisième trimestre 2025 et point sur les activités de la Société
20/11/2025
Trésorerie et équivalents de trésorerie s’élevant à 119,0 millions d’euros au 30 septembre 2025 39,2 millions d’euros de revenus pour les neuf premiers mois de 2025, incluant un paiement d’étape de 26,5 millions d’euros [...]
GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update
20/11/2025
Cash and cash equivalents totaled €119.0 million as of September 30, 2025 €39.2 million in revenues for the nine months ended September 30, 2025, including the €26.5 million milestone payment following pricing and [...]
Medx Holdings Posts Strong Q3 Momentum and Reinforces Its Foundation Ahead of 2026 Expansion
20/11/2025
Medx Posts Strong Q3 Reports Austin Texas, Nov. 20, 2025 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE MedX Holdings, Inc. (OTC: MEDH) LazyDaze Posts Strong Q3 Momentum and Reinforces Its Foundation Ahead of 2026 Expansion [...]
DLH to Announce Fiscal 2025 Fourth Quarter Financial Results
20/11/2025
ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital [...]
Grant of Restricted Stock Units and Warrants to Employees in Genmab
20/11/2025
Company Announcement COPENHAGEN, Denmark; November 20, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 6,933 restricted stock units and 7,377 warrants to employees of the [...]
Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study
20/11/2025
-- Evidence of Monotherapy Activity : Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second MEK-rechallenge 3rd- [...]
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
20/11/2025
BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
Keros Therapeutics Announces Final Results of Tender Offer
20/11/2025
LEXINGTON, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the final results of its cash tender offer (the “Tender Offer”) to repurchase up to [...]
Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference
20/11/2025
PURCHASE, N.Y., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced that the [...]
Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
20/11/2025
SAN FRANCISCO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
20/11/2025
Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, [...]

Pages